Method for the treatment of menopausal syndrome in men

 

(57) Abstract:

The invention relates to medicine, in particular to andrology, and can be used for the treatment of menopausal syndrome in men. Make a preliminary assessment of the degree of violation of the copulative function on the scale of its quantitative estimation of O. B. Laurent and A. S. Segal, 1998, When the deviation amount of points from the average norm for men 51-65 years spend intravenous infusions of ozonated saline solution. When the deviation amount of points on 1-4 intravenously injected with 200 ml of 0.9% ozonated solution with ozone concentration of 1.5-2.5 mg/l 3 times per week, total number 3-4. When the deviation amount of points on 5-8 intravenously injected with 200 ml of 0.9% ozonated solution with ozone concentration of 2.5-3.0 mg/l 3 times per week, just 6-7. When the deviation amount of points on 9-12 intravenously injected with 200 ml of 0.9% ozonated solution with ozone concentration of 3.5-4.5 mg/l 3 times per week, only 9-10. When the deviation amount of points on 13-14 intravenously injected with 200 ml of 0.9% ozonated solution with ozone concentration of 5.0-5.5 mg/l 3 times per week, around 10-12. When the deviation amount of points from the average standards by neurohumoral component 2 and above in addition enter the Andes is the fact that on 2 or more additionally spend vibratory erogenous reflexogenic zones with a frequency of 150-250 Hz and a pressure of 150-300 KPa 1-1,5 min on each zone. The method corrects erectile dysfunction resulting from age-related involutional changes. 1 AD. and 2 C.p. f-crystals, 1 table.

The invention relates to medicine and can be applied in urology and sexologist for the treatment of erectile dysfunction in the background of pronounced menopausal disorders.

Known application of electrophoresis of different vasoactive drugs for the treatment of climacteric disorders in men Karpukhin N. In. “Electrophoresis sinusoidal modulated currents vasoactive drugs in the treatment of patients with impotence, Issues of balneology, physiotherapy and kinesitherapy, No. 3, 1994, S. 24).

Known erectile dysfunction treatment by yohimbine and arginine to treat erectile dysfunction (application 2000100301/14 published 06.07.1998.), we have made as a prototype. However, despite widespread in clinical practice, this method of treatment erectile dysfunction is ineffective.

In order to increase the effectiveness of the treatment of menopausal syndrome in men, integral part of which is erectile dysfunction, we offer a method of ozone therapy of this pathology. Us oz is about the past is an integral part of the climacteric syndrome. Attempts have been made to ensure yohimbinum, Sustanon, andriola, intracavernous injection of drugs PRE, traditional physical therapy has been unsuccessful, that was understandable after a thorough and comprehensive study patients, which found that erectile failure in the study group occurred not only due to endocrine disorders due to climacteric syndrome, and developed complex psychosomatic disorders of the whole organism.

The problem is solved in that the pre-evaluate the degree of disturbance copulative function on a scale µf and when the degree of deviation of the copulative function of the average age norms from 1 to 4 carry out intravenous infusion of 200 ml of 0.9% ozonized physiological solution with an initial ozone concentration of 1.5-2.5 mg/l 3 times per week, total number of infusions 3-4;

when the degree of deviation of the copulative function from 4 to 8 in/enter in 200 ml of 0.9% ozonized saline solution with an initial ozone concentration of 2.5-3.0 mg/l 3 times per week, only 6-7 infusion;

when the degree of deviation of the copulative function from 8 to 12 introducing 200 ml of 0.9% ozonized saline solution with initial concentrat the t 12 to 14 introducing 200 ml of 0.9% ozonized saline solution with an initial ozone concentration of 5.0-5.5 mg/l, 3 times a week, just 10-12 infusion;

moreover, when the degree of deviation on the block I (neurohumoral component) from 2 or more additionally for the entire course enter andriol 120 mg/day, once a day throughout the course of ozone therapy, and when the degree of deviation on block 3 (erectile function) of 2 or higher is conducted additionally vibratory erogenous reflexogenic zones with a frequency of 150-250 Hz and a pressure of 150-300 KPa 1-1,5 min on each zone.

The method is as follows.

The ozonized physiological solution produced by setting ozonoterapiya automatic with ozone destructor WATA-60-01 “MADISON”, allows you to smoothly adjust the ozone concentration in the ozone-oxygen mixture at the outlet from 0 to 60 mg/l and to measure the concentration of ozone in the ozonized physiological solution. Installation powered by compressed oxygen with positive pressure on the input set from 45 to 400 kPa. The installation consists of an ozone generator, the input of the gearbox, valve fine adjustment of the flow rate of oxygen, unit of measurement, unit of catalytic ozone decomposition unit microprocessor control. The oxygen through the inlet port enters the ed and and the flow meter oxygen enters into the inlet valve, operated by the microprocessor. When you click “START”, the microprocessor opens the inlet valve and the flow of oxygen gets into the ozonizer and then in the photometric unit for continuous measurement of ozone concentration in the oxygen flow. After measuring unit ozone-oxygen mixture through the nozzle “OZONE” is adjudged to be in an external device. Residual ozone through fitting “RESET” falls into the trap moisture and then to block the catalytic decomposition of residual ozone. Managing the installation and measurement of parameters it is microprocessor unit. The measurement results are displayed on the LCD screen: the concentration of ozone in gas and liquid in digital form, in mg/l; flow rate of the gas mixture - graphically, in the form of a column whose height is proportional to the flow velocity.

Male copulative function was investigated using scale quantitative assessment of male copulative function (scale áf) [O. B. Laurent, A. S. Segal, 1998]. The authors emphasize that one of the key features of the evaluation of patients sexological profile is the scarcity of detectable pathological changes, and sometimes in their complete absence. The expert opinion is based on the analysis of complaints b is O. B. Laurent and A. S. Segal and common summary assessment of male copulative function among doctors, urologists and sexologists in the territory of the Russian Federation. Methods of assessment on a scale ICF approved and adopted by the European Association of urology and the Russian society of urologists. In the most part of modern scientific research in andrology and urology as a comprehensive assessment of the scale is applied UF. Scale áf is designed to detect, total quantitative assessment and monitoring of disorders of the male copulative function and to monitor the effectiveness of corrective actions. The scale includes a number of indicators (questions), denoted by Roman numerals from I to XIII. For each question from 6 suggested answers the patient selects the one corresponding to his situation. Each answer has a score in points from 0 to 5, that is, from the extreme extent of disturbance to the extreme severity of the analyzed parameters. Answer with score 5 points for each indicator from I to XII reflects sexual reactions inherent in the period of youth hypersexuality, as well as those with a strong type of sexual Constitution. Maximum total points for all indicators will be equal to 60 (12×5). Score 4 points reflects the sexual manifestations, the corresponding average rate for men aged 20 to 35 years (maximum average amount of points - 48), 3 years (the maximum amount is 12). Response assessed a score of 0 indicates extreme violations of the analyzed parameters. Scale áf is made in such a way that allows not only to identify sexual violation, but also to carry out structural analysis, i.e. to detect the defeat of the individual components of the copulative cycle. Thus, the indices I, II and III is characterized mainly neurohumoral component copulative cycle, IV and V - mental component, II, III and VI - erectile component, VII, VIII and IX - ejaculatory component, X, XI and XII are a function of the copulatory system as a whole. Figure XIII shows the opinion of the Respondent about his sexual potency in General. Completed patient questionnaire scale áf is analyzed by the doctor. First of all the sum of points from I to XII index, which reflects the General condition of the copulative function in a given period of time. Then the calculated amount is matched with the amount of points corresponding to the average normal for the patient's age. Obtained by subtracting the number will be proportional to the degree of deviation of the copulative function of the average age norms. Similarly, the analysis of figure XIII, reflecting intelligent character, than the sum of points from I to XII figure, the mapping may reveal the tendency of the patient to exaggerate or understate the severity and importance of sexual disorders. In the next step, structural analysis, that is determined by the presence and degree of involvement of the individual components in sexual dysfunction. The total points scored by the patient on each block of the three indices (I, II, III - neurohumoral component; II, III, VI - erectile component; VII, VIII, IX - ejaculatory component; X, XI, XII - copulative function of the whole system) maps to the sum of the scores corresponding to the average normal for the age of the patients: max - 15 (maximum score multiplied by the number of indicators 5×3) from 20 to 35 years old- 12 (4×3), from 36 to 50 years old- 9 (3×3), from 51 to 65 years old- 6 (2×3), over 65 years- 3 (1×3), from 0 to 3 points - extreme violations. Similarly assesses the mental component, represented by a block of two indicators - IV and V (maximum score - 10).

The age profile of patients treated by the proposed methods were 51-65 years. After assessing deviations of parameters of male copulative function from segnestam the AI 200 ml of 0.9% ozonized physiological solution with an initial ozone concentration of 1.5-2.5 mg/l, 3 times a week, the total number of infusion 3-4;

when the degree of deviation from 4 to 8 in/enter in 200 ml of 0.9% ozonized saline solution with an initial ozone concentration of 2.5-3.0 mg/l 3 times per week, only 6-7 infusion;

when the degree of deviation from 8 to 12 introducing 200 ml of 0.9% ozonized saline solution with an initial ozone concentration of 3.5-4.5 mg/l 3 times per week, only 9-10 infusion;

when the degree of deviation from 12 to 14 introducing 200 ml of 0.9% ozonized saline solution with an initial ozone concentration of 5.0-5.5 mg/l 3 times per week, around 10-12 infusions; and, as has been shown in clinical studies, when significant deviations from the norm in neurohumoral component (2 and above), and in the erection component (2 and above), monotherapy with ozone is ineffective, and therefore advanced in the first case, enter andriol 120 mg/day, once a day throughout the course of ozone therapy, and the second is conducted additionally vibratory erogenous reflexogenic zones with a frequency of 150-250 Hz and a pressure of 150-300 KPa 1-1,5 min on each zone (see table).

As can be seen from the table, the dynamics of indicators of male copulative function shows the largest positive shifts UF when applying ozonating (P<0,05). Also noted significant improvement in erectile component of the ICF in patients of the third group (P<0,05), which may be related to the stimulation of the production of nitrogen monoxide (NO) under the action of ozone therapy. Indicators of mental, ejaculatory components and the total valuation IFF significantly higher in patients of the third group.

Clinical examples of the method

Example 1

Patient T., 58 years. Appealed with complaints of erectile dysfunction about 8 months, poor sleep, fatigue. Erection occurs rarely, incomplete. It was treated at the sexologist with the use of LD therapy, drug therapy. When reallocations study eographically index of 0.9, microtechnique index 35%. When assessing the copulative function on a scale UF was revealed the degree of deviation of 5, with the degree of deviation in cock part 2. Treatment: in/drip, with a speed of 400 drops/min, through the day, was introduced 200 ml of 0.9% ozonized saline solution with an initial ozone concentration of 2.7 mg/l, simultaneously with ozone therapy conducted vibratory erogenous reflexogenic zones with a frequency of 150-250 Hz and a pressure of 150-300 KPa 1-1,5 min on each zone.

After 4 treatments of ozone therapy the emergence of persistent erections of the spontaneous and adequate (in terms of specific stimulation of the penis). Started sexual life, successfully conducted the coitus. Indicators reallocations studies have shown that eographically index was 1.6, microtechnique index 60%. Assessment on a scale µf began to meet age requirements.

Example 2

Patient K., 64 years old, suffers from erectile dysfunction 1.7 years, against which notes irritability, fatigue, insomnia. Erection occurs rarely, weakened duration 1-1,5 minutes was Treated at the urologist (LD therapy, drug therapy) without positive effect. Eographically index of 0.9, microtechnique index 35%. When assessing the copulative function revealed the degree of deviation of 9 with the degree of deviation in neurohumoral component 3. Was held the following treatment: in/drip, with a speed of 180 drops/min, through the day, was introduced 200 ml of 0.9% ozonized saline solution with an initial ozone concentration of 4.0 mg/l, at the rate of 10 injections, with the second day ozone was introduced andriol 120 mg/day, once a day throughout the course of ozone therapy. After 4 treatments of ozone therapy, the patient was noted that the erection between infusions. After 8 proceed is as sufficient for the introduction of the penis and holding intercourse for 3-4 minutes Improved sleep, stopped bouts of irritability. Indicators reallocations study were: eographically index was 1.6, microtechnique index 60%. Assessment on a scale µf began to meet age requirements.

The claimed method was applied in 18 patients after a course of ozone therapy 14 were able to engage in intercourse, normalized psychological status, 4 patients refused further treatment for material reasons.

Thus, the dynamics of clinical symptoms and mental status of patients with climacteric syndrome within 12 months observations demonstrate the advantage of the new technologies of complex treatment of patients with the use of ozone therapy over traditional treatment methods.

1. Method for the treatment of menopausal syndrome in men, characterized in that the pre-evaluate the degree of disturbance copulative function on the scale of its quantitative estimation of O. B. Laurent and A. S. Segal, 1998, and when the deviation amount of points from the average norm for men 51-65 years 1-4 carry out intravenous infusion of 200 ml of 0.9% aqueous ozonized physiological solution with concentric the ml 0.9% ozonized saline solution with an ozone concentration of 2.5-3.0 mg/l, 3 times a week, just 6-7 infusion; when the deviation amount of points on 9-12 in/enter in 200 ml of 0.9% aqueous ozonized saline solution with an ozone concentration of 3.5-4.5 mg/l 3 times per week, only 9-10 infusion; when the deviation amount of points on 13-14 in/enter in 200 ml of 0.9% aqueous ozonized saline solution with an ozone concentration of 5.0-5.5 mg/l 3 times per week, around 10-12 infusions.

2. The method according to p. 1, wherein when the deviation amount of points on neurohumoral component 2 and above, additionally throughout the course of ozone therapy is administered andriol 120 mg/day, once a day.

3. The method according to p. 1, wherein when the deviation amount of points on cock part 2 and above, additionally spend vibratory erogenous reflexogenic zones with a frequency of 150-250 Hz and a pressure of 150-300 kPa 1-1,5 min on each zone.



 

Same patents:

The invention relates to improved compositions for injection of vasodilator agents in the human blood circulatory system to modulate sexual response on demand

The invention relates to the field of medicine and relates to the application of metabolite of sibutramine as a new drug to treat attention deficit or attention deficit hyperactivity disorder

The invention relates to medicine and can be used to obtain biologically active substances from the blood serum of animals and birds, are useful for the treatment or correction of a hearing impairment, sexual activity, spatial memory; and to increase physical endurance, stimulate proliferation of embryonic brain cells; useful in Parkinson's disease

The invention relates to medicine, in particular to urology, andrology and sexual pathology, and can be used in the conditions of policlinic, hospital and sanatorium-resort establishments

The invention relates to new nitrogen-containing aromatic 6-membered cyclic compounds of the formula (I) or their pharmaceutically acceptable salts, demonstrating excellent selective PDE V inhibitory activity

The invention relates to chemical-pharmacological industry and relates to a new means for treatment of violations of erection, containing derivative 3(2H)-pyridazinone, which is 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-(3-pyridylmethylamine)-3(2H)-pyridazinone or 4-bromo-6-[3-(4-chlorophenyl)-3-hydroxypropoxy]-5-(3-pyridylmethylamine)-3(2H)-pyridazinone or its pharmaceutically acceptable salt

The invention relates to a derivative phthalazine General formula (I) or their pharmaceutically acceptable salts, or hydrates, where R1and R2are the same or different from each other and each represents a halogen atom, a C1-C4alkyl group which may be substituted by a halogen atom, a hydroxyl group or a C1-C4alkoxygroup, which may be substituted by a halogen atom, or cyano; X represents a cyano, a halogen atom, hydroxyimino, optional O-substituted C1-C4alkyl group, or a heteroaryl group selected from thiazoline, thienyl, pyrazolidine, triazolinones and tetrazolyl groups that may be substituted WITH1-C4alkyl group; Y represents a cyclic amino group (i) - (v) described in paragraph 1 of the claims; (vi) etinilnoy or ethyl group substituted WITH1-C4alkyl group, which, in turn, replaced by a number of deputies referred to in paragraph 1 of the claims; (vii) optionally substituted phenyl group; (viii) pyridyloxy or thiazolidine group
The invention relates to medicine, namely to the treatment and prevention of erectile dysfunction in men, sexually active, and also during periods of sexual partners

The invention relates to new thienopyrimidine formula I, their pharmaceutically acceptable salts, having the effect of inhibitors of phosphodiesterase V, which can be used to combat diseases of the cardiovascular system and for the treatment and/or therapy of disorders, to pharmaceutical compositions in a form suitable for the treatment
The invention relates to medicine and to raise the sexual activity of man and animals

The invention relates to medicine, namely, neurology, and can be used in the treatment of cerebral palsy

The invention relates to medicine, namely to multicomponent infusion solutions with detoxification, hepatoprotective effect, and can be used in the intoxication of the organism of various severity
The invention relates to medicine, in particular to neuropathology and treatment of neurological manifestations of osteochondrosis physical factors, and can be used in hospitals, clinics, sanatoria, preventoria, home

The invention relates to the field creating means having an antimicrobial effect on local purulent-inflammatory processes of the soft tissues
The invention relates to medicine, in particular, to obstetrics

The invention relates to medicine, in particular to the gynecologist, and can be used in the treatment of diseases of the vagina

The invention relates to the field of neurological diseases and can be used in complex treatment of patients with acute and chronic pain syndromes
The invention relates to the field of medicine

The invention relates to medicine, to afferent therapy, and can be used to treat hepatorenal syndrome in patients with decompensated liver cirrhosis complicated by ascites syndrome
The invention relates to medicine, namely to dermatology

The invention relates to medicine, obstetrics, and can be used to increase nonspecific resistance of the pregnant woman to the generic act
Up!